Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials

BACKGROUND: The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six diseases. However, a subgroup analysis of Crohn’s disease (CD) in the main trial displayed a close to significant difference favouring...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BioDrugs
Main Authors: Jørgensen, Kristin K., Goll, Guro L., Sexton, Joe, Bolstad, Nils, Olsen, Inge C., Asak, Øivind, Berset, Ingrid P., Blomgren, Ingrid M., Dvergsnes, Katrine, Florholmen, Jon, Frigstad, Svein O., Henriksen, Magne, Hagfors, Jon, Huppertz-Hauss, Gert, Haavardsholm, Espen A., Klaasen, Rolf A., Moum, Bjørn, Noraberg, Geir, Prestegård, Ulf, Rydning, Jan H., Sagatun, Liv, Seeberg, Kathrine A., Torp, Roald, Vold, Cecilia, Warren, David J., Ystrøm, Carl M., Lundin, Knut E. A., Kvien, Tore, Jahnsen, Jørgen
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2020
Teme:
Original Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7519917/
https://ncbi.nlm.nih.gov/pubmed/32965617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-020-00438-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki